1444 related articles for article (PubMed ID: 8819129)
1. Low-dose integrated chemoimmuno-hormonotherapy with cisplatin, subcutaneous interleukin-2, alpha-interferon and tamoxifen for advanced metastatic melanoma--a pilot study.
Bernengo MG; Doveil GC; Bertero M; Quaglino P; Fierro MT; Savoia P; Appino A; Colonna S
Melanoma Res; 1996 Jun; 6(3):257-65. PubMed ID: 8819129
[TBL] [Abstract][Full Text] [Related]
2. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
3. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
Atzpodien J; Lopez Hänninen E; Kirchner H; Franzke A; Körfer A; Volkenandt M; Duensing S; Schomburg A; Chaitchik S; Poliwoda H
Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
Johnston SR; Constenla DO; Moore J; Atkinson H; A'Hern RP; Dadian G; Riches PG; Gore ME
Br J Cancer; 1998 Apr; 77(8):1280-6. PubMed ID: 9579834
[TBL] [Abstract][Full Text] [Related]
5. Adoptive immunotherapy with tumor-infiltrating lymphocytes and subcutaneous recombinant interleukin-2 plus interferon alfa-2a for melanoma patients with nonresectable distant disease: a phase I/II pilot trial. Melanoma Istituto Scientifico Tumori Group.
Queirolo P; Ponte M; Gipponi M; Cafiero F; Peressini A; Semino C; Pietra G; Lionetto R; Vecchio S; Ribizzi I; Melioli G; Sertoli MR
Ann Surg Oncol; 1999; 6(3):272-8. PubMed ID: 10340886
[TBL] [Abstract][Full Text] [Related]
6. Immunological and clinical effects of intramuscular rIFN alpha-2a and low dose subcutaneous rIL-2 in patients with advanced malignant melanoma.
Castello G; Comella P; Manzo T; Napolitano M; Parziale AP; Galati MG; Daponte A; Casaretti R; Celentano E; Comella G
Melanoma Res; 1993 Feb; 3(1):43-9. PubMed ID: 8471836
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of tamoxifen combined with cisplatin-interleukin 2 and alpha-interferon in metastatic melanoma.
Antoine EC; Rixe O; Vuillemin E; Benhammouda A; Borel C; Ghironzi GC; Mularoni E; Franks C; Auclerc G; Soubrane C
Am J Clin Oncol; 1995 Oct; 18(5):421-4. PubMed ID: 7572760
[TBL] [Abstract][Full Text] [Related]
8. Immunochemotherapy with recombinant interferon-alpha 2b plus dacarbazine in the treatment of advanced malignant melanoma.
Strojan P; Rudolf Z
Melanoma Res; 1997 Oct; 7(5):420-7. PubMed ID: 9429226
[TBL] [Abstract][Full Text] [Related]
9. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma.
Khayat D; Borel C; Tourani JM; Benhammouda A; Antoine E; Rixe O; Vuillemin E; Bazex PA; Thill L; Franks R
J Clin Oncol; 1993 Nov; 11(11):2173-80. PubMed ID: 8229131
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
Dillman RO; Soori G; Wiemann MC; Schulof R; Dobbs TW; Ruben RH; DePriest CB; Church C
Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-2-based immunotherapy and chemoimmunotherapy in metastatic melanoma.
Keilholz U; Scheibenbogen C; Brossart P; Möhler T; Tilgen W; Hunstein W
Recent Results Cancer Res; 1995; 139():383-90. PubMed ID: 7597305
[TBL] [Abstract][Full Text] [Related]
12. The feasibility of repetitive courses of high-dose continuous intravenous infusion interleukin-2 and subcutaneous alpha-interferon with polychemotherapy in advanced malignant melanoma.
Foppoli M; Citterio G; Polastri D; Guerrieri R
Tumori; 1995; 81(2):102-6. PubMed ID: 7778212
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study.
Dorval T; Négrier S; Chevreau C; Avril MF; Baume D; Cupissol D; Oskam R; de Peuter R; Vinke J; Herrera A; Escudier B
Cancer; 1999 Mar; 85(5):1060-6. PubMed ID: 10091789
[TBL] [Abstract][Full Text] [Related]
14. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
[TBL] [Abstract][Full Text] [Related]
15. Chemoimmunotherapy of metastatic malignant melanoma. The Salpétrière Hospital (SOMPS) experience.
Khayat D; Antoine E; Rixe O; Tourani JM; Vuillemin E; Borel C; Benhammouda A; Thill L; Franks C; Auclerc G
Eur J Cancer; 1993; 29A Suppl 5():S2-5. PubMed ID: 8260262
[TBL] [Abstract][Full Text] [Related]
16. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
Lissoni P; Vaghi M; Ardizzoia A; Malugani F; Fumagalli E; Bordin V; Fumagalli L; Bordoni A; Mengo S; Gardani GS; Tancini G
In Vivo; 2002; 16(2):93-6. PubMed ID: 12073777
[TBL] [Abstract][Full Text] [Related]
18. DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma.
Buzaid AC; Ali-Osman F; Akande N; Grimm EA; Lee JJ; Bedikian A; Eton O; Papadopoulos N; Plager C; Legha SS; Benjamin RS
Melanoma Res; 1998 Apr; 8(2):145-8. PubMed ID: 9610867
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.
Dutcher JP; Atkins M; Fisher R; Weiss G; Margolin K; Aronson F; Sosman J; Lotze M; Gordon M; Logan T; Mier J
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S73-8. PubMed ID: 9457399
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of interferon-alpha 2b with dacarbazine, carmustine, cisplatin and tamoxifen in metastatic melanoma.
Schultz MZ; Buzaid AC; Poo WJ
Melanoma Res; 1997 Apr; 7(2):147-51. PubMed ID: 9167181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
